Skip to content
The Kids Research Institute Australia logo

Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network

Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network.

Citation:
Wadia U, Richmond PC, Britton PN, Carr J, ……. Moore HC, Effler PV, Cheng AC, Blyth CC, Kotsimbos T, et al. Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network. Lancet Reg Health West Pac. 2026;73. 

Keywords:
RSV; Maternal vaccine; RSV monoclonal antibodies; Effectiveness; Nirsevimab; Children; Hospitalisation; Infant

Abstract:
Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network.